Does anyone know more about this study? How you qualify and how to get involved

 Dr. Sperling is leading a groundbreaking new study on individuals whose brain scans show plaque buildups but do not yet demonstrate clinical symptoms of Alzheimer’s or other dementias. She will be testing the effectiveness of the Eli Lilly drug solanezumab, which in previous studies has shown might have promise with people that have a milder form of Alzheimer’

The trial will enroll 1,000 people 70 and older with evidence of amyloid in their brains (by amyloid PET), but who do not show clinical symptoms of the disease.

I'm not finding anything else -- it does not appear to be posted at clinicaltrial.gov yet.

I wonder if this study on solanezumab is related to a drink called sovanaid in England and that is why it's not listed on Trial Match (because it's considered a supplement and not a pharmacological).  Here's an article on sovanaid: 

http://www.telegraph.co.uk/health/elderhealth/9784141/A-glimmer-of-hope-for-dementia-sufferers.html 

I live Wisconsin and am 55years old. My neurologist works at Froedert Hospital in  Milwaukee. We have a ARDC Madison.

I don't know where to start looking, I thought i saw somewhere that you had to be older and met some other criteria that I didn't meet?

Yes, I would love to hear what your Dr says about "catching it" early? Is your Dr who specializes in Alz and other Dementias including MCI?

It is so hard to find others with a MCI diagnosis and when you do there is so much differing opinions about what MCI will lead to.

I was told to get my affairs in order two years ago and did. I would like having another person with MCI to chat with. Do you use FaceBook maybe we can connect that way?

I'm in the MCI stage of Alzheimer's, but because I have the Presenilin 1 gene I will eventually go into Alzheimer's if a cure or something to stop the progression doesn't come along.  

Mild cognitive impairment causes cognitive changes that are serious enough to be noticed by the individuals experiencing them or to other people, but the changes are not severe enough to interfere with daily life or independent function.  

Because the changes caused by MCI are not severe enough to affect your daily life, MCI does not meet diagnostic guidelines for dementia. However, those with MCI have an increased risk of eventually developing Alzheimer's or another type of dementia. However, not all people with MCI get worse and some eventually get better.  

Solanezumab is a drug designed to lower amyloid plaque levels.  It showed no efficacy for people with Alzheimer's beyond the mild stages of the disease and showed very little efficacy for those in the mild stages.   

Eli Lily--the manufacturer of the drug--has convinced Dr. Sperling to study the drug as a possible preventive measure in people with high amyloid plaque levels.  Eli Lily also controls an imaging agent for amyloid plaques, so if their hypothesis that Alzheimer's disease can be prevented by removing amyloid plaques, it will be a double victory for them. 

Two problems, though.  Solanezumab does not remove all of the plaques and amyloid plaques are only a so-so predictor of the progression from MCI to Alzheimer's disease. 

A much better predictor is myo-inositol. 

VIENNA, Austria -- March 12, 2013 -- Myo-Inositol and N-acetylaspartate are sensitive biomarkers for clinical conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD), according to a study presented here at the 25th Annual European Congress of Radiology (ECR).

Comparison of patients with progressive disease versus those who developed AD for the cingulate gyrus showed the increased myo-inositol-to-water ratio to be 72% predictive for dementia; similarly for the hippocampus, it was 70% predictive for dementia.

http://www.docguide.com/myo-inositol-n-acetylaspartate-are-sensitive-biomarkers-conversion-mci-alzheimers-disease?tsid=5 

Myo-inositol is the precursor molecule to amyloid plaques and more importantly to peroxynitrites.  It also (like the presenilin 1 gene mutation) appears to cut of the phosphatidylinositol 3 kinase/AKT pathway which is neuroprotective. 

Lithium and scyllo-inositol are known inhibitors of myo-inositol in the brain, but are not safe.  Ferulic acid and glucuronolactone may lower myo-inositol levels in the brain and are also peroxynitrite scavengers, but their efficacy and safety are not fully known.  

.

Hi, Lisa.  Myriam has an extremely rare condition that is found in only a handful of families in the world.  In families with "early-onset familial Alzheimer's disease (eFAD)", the disease typically strikes at a very young age -- often in the 40s or 50s -- and appears at such a young age in every generation.

So, for you to have one of the eFAD genes, one of your parents would have had Alzheimer's when they were very young, and one of that parent's parents would have had Alzheimer's when they were very young, and so on.

The vast majority of Alzheimer's -- including the vast majority of young-onset -- is what is called "sporadic".  It is not inherited per se.  There are certain genes that increase your risk of developing Alzheimer's, such as the APOE4 allele, but you can carry those genes and never develop the disease ... and you can develop Alzheimer's without carrying those genes.